New imaging method for evaluating transport of oxygen to cells

STOCKHOLM – MARCH 30, 2023 – In cooperation with Perimed AB, researchers from the Department of Biomedical Engineering at Linköping University, Sweden, have developed a new method for imaging microvascular blood flow in video-rate that enables new aspects of evaluating the vital transport of oxygen to cells. The method was published in the latest issue of Journal of Biomedical Optics, which is a leading journal within the field.

“Microcirculation is a critical function in our body and often affected by diseases such as diabetes, endothelial dysfunction, and sepsis. Understanding this process in more detail enables clinicians to take scientific-based decisions and ensure that these growing patient groups receive accurate and timely care. This is novel cutting-edge research promising an unprecedented understanding of this vital function”, says Lena Åredal, CEO at Perimed.

The method utilizes ultra-parallel computations of data from a high-speed image sensor, implemented in a programmable electronic chip. This results in so called multi-exposure laser speckle contrast images, that are further analyzed by artificial intelligence, resulting in a novel measure of tissue blood flow with quality not seen before. Even more importantly, the new method enables distinction between different vessel compartments based on flow speed.

The new aspects of the microcirculatory blood flow that can be studied with the technique give opportunities for better diagnosis of vascular diseases such as diabetic foot ulcers. It is an important step in Perimed’s vision to improve the quality of life for people suffering from vascular diseases.

This research would not have been possible without the well-established cooperation between Perimed AB and the researchers at Linköping University, promoted by Vinnova – Sweden’s innovation agency, and their strategic innovation programs Medtech4Health and Swelife.

Read the whole open access journal paper here:

Perimed today announces that the company’s products, quality system and manufacturing facility has been certified in accordance with the new European Medical Device Regulation (MDR)

Safety and effectiveness are focus areas for us as a medical device company. By continuously adapting to meet the Quality and Regulatory requirements during the product life cycle through an effective and practical Quality Management System and procedures, we maintain our competitive edge.

“Our vision is to save limbs, lives and reduce human suffering and one of our value statements is to have Compliance in everything we do. I am so proud to have our team deliver on this important milestone without receiving any non-conformances.”, says Lena Åredal, CEO at Perimed.

The European Medical Devices Regulation 2017/745 (MDR) is applicable in Europe, replacing the Medical Devices Directive (93/42/EEC) and introducing major changes to how medical device manufacturers obtain European market access. This transition involves an increased work effort compared to the previous regulation, since the MDR introduces a life-cycle approach for the CE Marking Compliance and introduces several new requirements.

Perimed Inc, a Global Leader in the Field of Peripheral Vascular Diagnosis, Awarded Agreement with Premier Inc.

LAS VEGAS – NOVEMBER 15, 2022 – Perimed Inc has been awarded a group purchasing agreement with Premier Inc effective September 1st, 2022. The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the PeriFlux 6000 and its disposables. The PeriFlux 6000 is a state-of-the-art system for quick and accurate assessment of patients suffering from peripheral vascular disease.

Vascular disease is one of the world’s fastest growing health issues and is often associated with diabetic foot ulcers. At least 15% of the diabetic population will develop a foot ulcer in their lifetime. By not properly evaluating the vascular problem, the risk of the non-healing wound leading to amputation is highly increased. Currently, 14-24% of the ulcer patients require an amputation. The estimated annual direct cost of diabetic foot ulcers in the US is at least $17 billion which is higher than the costliest cancers, such as breast cancer and colorectal cancer.

Our clinical tools provide a complete combination of vascular tests, securing accurate diagnosis of patients with peripheral arterial disease. The PeriFlux 6000 System is the only device that can perform all the non-invasive vascular measurements recommended by the Global Vascular Guidelines in one visit.

The collaboration with Premier is a fantastic milestone for Perimed and one of the most important agreements we have entered into to date. Our vision is to save limbs, lives and human suffering. This strategic agreement enables us to rapidly expand our footprint in the US, making our state-of-the-art technology even more easily accessible to customers”, says Lena Åredal, CEO at Perimed.

Premier is a leading healthcare improvement company, uniting an alliance of more than 4,400 US hospitals and approximately 250,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, consulting and other services, Premier enables better care and outcomes at a lower cost.


  1. Conte et al. Global Vascular Guidelines 2019
  2. David Armstrong et al; Diabetic Foot Ulcers, Prevention, Diagnosis and Classification
  3. Oliver TI el al, Diabetic Foot: Facts and Figures